Protocol Ledger

NCT03610971 · Phase II · ACTIVE NOT RECRUITING

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

Interventional Phase II clinical trial protocol NCT03610971 sponsored by H. Lee Moffitt Cancer Center and Research Institute in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-11-19 Enrollment: 24 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03610971
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)24 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03610971
Protocol FieldVerified Registry Value
NCT IdentifierNCT03610971
Consolidated Lead SponsorH. Lee Moffitt Cancer Center and Research Institute
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment24 participants (ACTUAL)
Registered Start Date2019-11-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Moffitt Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI